Neurotrope is a biopharmaceutical company with product candidates in pre-clinical and clinical development. Co. is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. Co. is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. In addition, Co. is also in the early stages of testing bryostatin activity which may lead to applications in Leukemia and Lymphoma. We show 19 historical shares outstanding datapoints in our coverage of NTRP's shares outstanding history.
Understanding the changing numbers of NTRP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NTRP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NTRP by allowing them to research NTRP shares outstanding history
as well as any other stock in our coverage universe. |
Free NTRP Email Alerts:
Video: Shares Outstanding Importance
